Literature DB >> 1397053

Characterization of the novel 5-HT3 antagonists MDL 73147EF (dolasetron mesilate) and MDL 74156 in NG108-15 neuroblastoma x glioma cells.

P H Boeijinga1, M Galvan, B M Baron, M W Dudley, B W Siegel, A L Slone.   

Abstract

In radioligand binding experiments, MDL 73147EF and MDL 74156 inhibited the binding of [3H]GR65630 to 5-hydroxy-tryptamine3 (5-HT3) binding sites on membranes prepared from NG108-15 neuroblastoma x glioma cells. The calculated dissociation constants (KI) were 20.03 +/- 6.58 and 0.44 +/- 0.18 nM, respectively (means +/- S.E.M., n = 6 and 9, respectively). Application of 5-HT (10-50 microM) to voltage-clamped NG108-15 cells elicited a rapidly desensitizing inward membrane current, characteristic for the activation of 5-HT3 receptors. The 5-HT-induced membrane current was suppressed in a reversible, concentration-dependent manner by MDL 73147EF and MDL 74156EF. The concentrations required to block half the 5-HT response (IC50) were 3.8 and 0.1 nM, respectively. It is concluded that both compounds are potent and reversible antagonists at 5-HT3 receptors in this neuroblastoma cell line.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1397053     DOI: 10.1016/0014-2999(92)90573-m

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  8 in total

1.  A double-blind, multicentre comparison of intravenous dolasetron mesilate and metoclopramide in the prevention of nausea and vomiting in cancer patients receiving high-dose cisplatin chemotherapy.

Authors:  B Chevallier; P Cappelaere; T Splinter; M Fabbro; J L Wendling; L Cals; G Catimel; M Giovannini; D Khayat; P Bastit; N Claverie
Journal:  Support Care Cancer       Date:  1997-01       Impact factor: 3.603

2.  Open-label, randomized comparison of the efficacy of intravenous dolasetron mesylate and ondansetron in the prevention of acute and delayed cisplatin-induced emesis in cancer patients.

Authors:  Jin-Soo Kim; Ji Yeon Baek; Sook Ryun Park; In Sil Choi; Sang-Il Kim; Dong-Wan Kim; Seock-Ah Im; Tae-You Kim; Dae Seog Heo; Yung-Jue Bang; Noe Kyeong Kim
Journal:  Cancer Res Treat       Date:  2004-12-31       Impact factor: 4.679

Review 3.  The 5-HT3 receptor as a therapeutic target.

Authors:  Andrew J Thompson; Sarah C R Lummis
Journal:  Expert Opin Ther Targets       Date:  2007-04       Impact factor: 6.902

4.  Dose-ranging evaluation of the antiemetic efficacy of intravenous dolasetron in patients receiving chemotherapy with doxorubicin or cyclophosphamide.

Authors:  P J Hesketh; D R Gandara; A M Hesketh; A Facada; E A Perez; L M Webber; L A Martin; M B Cramer; W F Hahne
Journal:  Support Care Cancer       Date:  1996-03       Impact factor: 3.603

5.  Lack of analgesic efficacy of spinal ondansetron on thermal and mechanical hypersensitivity following spinal nerve ligation in the rat.

Authors:  Christopher M Peters; Ken-ichiro Hayashida; Eric E Ewan; Kunie Nakajima; Hideaki Obata; Qinghao Xu; Tony L Yaksh; James C Eisenach
Journal:  Brain Res       Date:  2010-07-15       Impact factor: 3.252

Review 6.  5-HT3 receptors.

Authors:  A J Thompson; S C R Lummis
Journal:  Curr Pharm Des       Date:  2006       Impact factor: 3.116

Review 7.  Dolasetron. A review of its pharmacology and therapeutic potential in the management of nausea and vomiting induced by chemotherapy, radiotherapy or surgery.

Authors:  J A Balfour; K L Goa
Journal:  Drugs       Date:  1997-08       Impact factor: 11.431

8.  Effects of 5-hydroxytryptamine on spermatozoal hyperactivation and in vitro fertilization in mice.

Authors:  Yukiko Sugiyama; Masakatsu Fujinoki; Hiroaki Shibahara
Journal:  J Reprod Dev       Date:  2019-11-06       Impact factor: 2.214

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.